User login
Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.
Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.
Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.
Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.
Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.
Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.
Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.
Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.
Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.
Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.
Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.
Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.
Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.
Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.
Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.